Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25094583 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Taichi Matsumoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Basic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Azacitidine, DNA Methylation, Arachidonate 12-Lipoxygenase. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI Grant-in-Aid for Scientific Research (C), JSPS KAKENHI Grant-in-Aid for Early-Career Scientists.
Abstract (Originalsprache)
5-azacytidine (AZA), a representative DNA-demethylating drug, has been widely used to treat myelodysplastic syndromes (MDS). However, it remains unclear whether AZA’s DNA demethylation of any specific gene is correlated with clinical responses to AZA. In this study, we investigated genes that could contribute to the development of evidence-based epigenetic therapeutics with AZA. A DNA microarray identified that AZA specifically upregulated the expression of 438 genes in AZA-sensitive MDS-L cells but not in AZA-resistant counterpart MDS-L/CDA cells. Of these 438 genes, the ALOX12 gene was hypermethylated in MDS-L cells but not in MDS-L/CDA cells. In addition, we further found that (1) the ALOX12 gene was hypermethylated in patients with MDS compared to healthy controls; (2) MDS classes with excess blasts showed a relatively lower expression of ALOX12 than other classes; (3) a lower expression of ALOX12 correlated with higher bone marrow blasts and a shorter survival in patients with MDS; and (4) an increased ALOX12 expression after AZA treatment was associated with a favorable response to AZA treatment. Taking these factors together, an enhanced expression of the ALOX12 gene may predict favorable therapeutic responses to AZA therapy in MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
- Department of Hematology, St. Mary's Hospital, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
ORCID-Profile: Taichi Matsumoto
Förderung
- Japan Society for the Promotion of Science
- JSPS KAKENHI Grant-in-Aid for Scientific Research (C)
- JSPS KAKENHI Grant-in-Aid for Early-Career Scientists
Zitieren
APA
Matsumoto, T., Murakami, Y., Yoshida-Sakai, N., Katsuchi, D., Kanazawa, K., Okamura, T., Imamura, Y., Ono, M., & Kuwano, M. (2024). Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094583
Vancouver
Matsumoto T, Murakami Y, Yoshida-Sakai N, Katsuchi D, Kanazawa K, Okamura T, et al. Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094583
BibTeX
@article{Matsumoto2024,
author = {Matsumoto, Taichi and Murakami, Yuichi and Yoshida-Sakai, Nao and Katsuchi, Daisuke and Kanazawa, Kuon and Okamura, Takashi and Imamura, Yutaka and Ono, Mayumi and Kuwano, Michihiko},
title = {Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25094583}
}
EUVIMED